Cold kits with Tc-99m labelling for diagnosis

Tc-IK-7

V09CA02

OGYI-T9245/01

Technetium (^99mTc) succimer injection

Dimercaptosuccinic acid

1.5 mg

• Stannous chloride dihydrate
• Ascorbic acid
• Calcium gluconate

• Kidney scintigraphy, static kidney imaging, localisation of the kidneys with imaging
• Determination of the functional mass of the kidney
• Determination of the relative function ratio (percentage) of the left and right kidneys

1.0–1.8 GBq

6 injection vials

See in the Summary of Product Charasteristics

24 months after radiolabelling: 8 h

2-8°C after radiolabelling: ≤ 25°C

Tc-IK-8

V09CA01

OGYI-T-9244/01

Technetium (^99mTc) pentate injection

Diethylenetriamino pentaacetic acid

9.0 mg

• Stannous chloride dihydrate
• Ascorbic acid
• Sodium chloride

• Dynamic studies of kidney, determination of kidney perfusion, glomerural filtration rate, total and partial kidney function
• Examination of the cerebral blood circulation
• Examination of the gastrointestinal tract by using labelled foodstuff or drink
• Examination of liquor circulation

0.8–2.4 GBq

6 injection vials

See in the Summary of Product Charasteristics

12 months after radiolabelling: 8 h

 ≤ 25°C after radiolabelling: ≤ 25°C

Tc-IK-25

V09CA

OGYI-T-9141/01

Technetium (^99mTc) EC injection

Ethylene-dicysteine

2.0 mg

Vial A

• Disodium hydrogen phosphate dihydrate
• Mannitol
• Ascorbic acid
• Sodium edetate

Vial B

• Stannous chloride dihydrate
• Ascorbic acid
• Tartaric acid

Vial C

• Potassium dihydrogen phosphate
• Ascorbic acid

• Dynamic studies of kidney for renal tubular function

0.8–1.6 GBq

3 x 4 injection vials

See in the Summary of Product Charasteristics

24 months after radiolabelling: 8 h

2-8°C after radiolabelling: ≤ 25°C

Tc-IK-5

V09BA03

OGYI-T9246/01

Technetium (^99mTc) tin pyrophosphate injection

Sodium pyrophosphate

25.0 mg

• Stannous chloride dihydrate
• Sodium chloride

• Bone and acute myocardial infarct scintigraphy
• Blood pool scintigraphy
• Spleen scintigraphy

1.3–3.0 GBq

6 injection vials

See in the Summary of Product Charasteristics

12 months after radiolabelling: 3 h

≤ 25°C after radiolabelling: ≤ 25°C

Tc-IK-10

V09BA02

OGYI-T9702/01

Technetium (^99mTc) medronate injection

Medronic acid

5.0 mg

• Stannous chloride dihydrate
• Ascorbic acid
• Urea

For bone scintigraphy (diagnostic skeletal imaging) Use of the preparation is highly recommended for:

• Primer bone tumours
• Metastases of other tumours, for example prostate/breast/lung cancer
• Osteomyelitis
• Metabolic bone diseases
• Paget’s disease

3.0–6.0 GBq

6 injection vials

See in the Summary of Product Charasteristics

12 months after radiolabelling: 6 h

2-8°C after radiolabelling: ≤ 25°C

Tc-IK-81

V09GA01

OGYI-T-23814/01

Technetium (^99mTc) sestamibi injection

[tetrakis (1-isocyanide-2-methoxy-2-methylpropyl-)copper(I)] tetrafluoroborate

1.0 mg

• Cysteine hydrochloride monohydrate
• Sodium citrate
• Stannous chloride dihydrate
• D-Mannitol

• Diagnosis of reduced coronary perfusion and myocardial infarction: 400 – 900 MBq
• Diagnosis of ischaemic heart disease:
  • Two-day protocol: 600 – 900 MBq /study
  • One-day protocol: 400 – 500 MBq for the first injection, three times more for the second injection
• Assessment of global ventricular function: 600 – 800 MBq injected as a bolus
• Scintimammography: 700 – 1000 MBq injected as a bolus
• Localisation of hyperfunctioning parathyroid tissue: 200 – 700 MBq injected as a bolus

max. 15.0 GBq

6 injection vials

See in the Summary of Product Charasteristics

24 months after radiolabelling: 16 h

2-8°C after radiolabelling: ≤ 25°C

Tc-IK-2

V09DB07

OGYI-T9288/01

Technetium (^99mTc) phytate injection

Sodium phytate

15.0 mg

• Stannous chloride dihydrate
• Sodium chloride

• Morphological examination of the liver by imaging technique
• Diagnosis of benign and malignant liver tumours and monitoring of the therapy

0.8–1.6 GBq

6 injection vials

See in the Summary of Product Charasteristics

12 months after radiolabelling: 3 h

≤ 25°C after radiolabelling: ≤ 25°C

Tc-IK-6

V09DA02

OGYI-T-9210/01

Technetium (^99mTc) etifenin injection

Diethyl-acetanilid-imino diacetic acid

30.0 mg

• Stannous chloride dihydrate
• Ascorbic acid

• Dynamic examination of the function of the hepatocytes
• Liver transplant evaluation
• Dynamic examination of flow disorders in the hepatobiliary system (blockage in the biliary duct, etc.)
• Examination of the acute cholecystitis
• Verification of focal nodular hyperplasia

0.8–1.6 GBq

6 injection vials

See in the Summary of Product Charasteristics

24 months after radiolabelling: 6 h

2-8°C after radiolabelling: 2-8°C